Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Lees

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Cancer Immunology Research|June 12, 2025
Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor That Unleashes PD-1 Checkpoint and CAR T-Cell ImmunotherapiesMichael Wichroski, Si-Qi Liu, Lauren M Zasadil, et al.
Journal of Medicinal Chemistry|October 14, 2025
Design, Synthesis, and T Cell Checkpoint Combination Potential Of First-In-Class DGKα/ζ Inhibitor BMS-986408Denise C Grünenfelder, Upender Velaparthi, Jayakumar S Warrier, et al.
Nature Medicine|October 20, 2015
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug responseHui Gao, Joshua M Korn, Stéphane Ferretti, et al.
Cell|July 29, 2017
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi ScreeningE Robert McDonald, Antoine de Weck, Michael R Schlabach, et al.
Cancer Cell|April 13, 2016
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in MiceElizabeth C Townsend, Mark A Murakami, Alexandra Christodoulou, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Cancer Immunology Research|June 12, 2025
Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor That Unleashes PD-1 Checkpoint and CAR T-Cell ImmunotherapiesMichael Wichroski, Si-Qi Liu, Lauren M Zasadil, et al.
Journal of Medicinal Chemistry|October 14, 2025
Design, Synthesis, and T Cell Checkpoint Combination Potential Of First-In-Class DGKα/ζ Inhibitor BMS-986408Denise C Grünenfelder, Upender Velaparthi, Jayakumar S Warrier, et al.
Nature Medicine|October 20, 2015
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug responseHui Gao, Joshua M Korn, Stéphane Ferretti, et al.
Cell|July 29, 2017
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi ScreeningE Robert McDonald, Antoine de Weck, Michael R Schlabach, et al.
Cancer Cell|April 13, 2016
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in MiceElizabeth C Townsend, Mark A Murakami, Alexandra Christodoulou, et al.
Pageof 4